Loading…
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $39M | $14M | $11M | $14M | 9.5% | -5.8% | -18.7% |
| 2024 | $41M | $16M | $14M | $15M | 11.8% | -18.6% | -16.6% |
| 2023 | $50M | $23M | $17M | $22M | 13.0% | -3.9% | 1.0% |
| 2022 | $52M | $27M | $16M | $20M | 14.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 52.28 | 50.22 | 40.90 | 38.52 |
| Operating Revenue | - | 52.28 | 50.22 | 40.90 | 38.52 |
| Cost Of Revenue | - | 20.08 | 20.19 | 16.76 | 16.52 |
| Gross Profit | - | 32.20 | 30.04 | 24.14 | 22 |
| Operating Expense | - | 12.41 | 13.26 | 10.55 | 10.60 |
| Research And Development | - | 0.49 | 0.56 | 0.81 | 0.67 |
| Selling General And Administration | - | 11.91 | 12.70 | 9.74 | 9.93 |
| Total Expenses | - | 32.49 | 33.45 | 27.31 | 27.12 |
| Operating Income | - | 19.79 | 16.78 | 13.59 | 11.40 |
| Total Operating Income As Reported | - | 19.79 | 16.78 | 13.59 | 11.40 |
| EBITDA | - | 26.87 | 23.14 | 16.44 | 14.41 |
| Normalized EBITDA | - | 26.21 | 20.11 | 13.07 | 11.60 |
| EBIT | - | 19.79 | 16.78 | 13.59 | 11.40 |
| Other Non Operating Income Expenses | - | 0.21 | 0.28 | -0.16 | -0.10 |
| Other Income Expense | - | 0.87 | 3.31 | 3.21 | 2.71 |
| Pretax Income | - | 20.66 | 20.09 | 16.80 | 14.11 |
| Tax Provision | - | 4.19 | 3.45 | 2.93 | 2.82 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.13 | 0.52 | 0.59 | 0.56 |
| Net Income Continuous Operations | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income From Continuing And Discontinued Operation | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income From Continuing Operation Net Minority Interest | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Common Stockholders | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Net Income Including Noncontrolling Interests | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Normalized Income | - | 15.95 | 14.12 | 11.09 | 9.04 |
| Diluted NI Availto Com Stockholders | - | 16.47 | 16.64 | 13.87 | 11.29 |
| Basic Average Shares | - | 3.63 | 3.63 | 3.34 | 3.19 |
| Diluted Average Shares | - | 3.64 | 3.64 | 3.50 | 3.24 |
| Reconciled Depreciation | - | 7.08 | 6.37 | 2.85 | 3.01 |
| Reconciled Cost Of Revenue | - | 20.08 | 20.19 | 16.76 | 16.52 |
| Total Unusual Items | - | 0.66 | 3.04 | 3.37 | 2.81 |
| Total Unusual Items Excluding Goodwill | - | 0.66 | 3.04 | 3.37 | 2.81 |
| Gain On Sale Of Security | - | 0.66 | 3.04 | 3.37 | 2.81 |
| General And Administrative Expense | - | 10.41 | 11.02 | 7.84 | 7.88 |
| Other Gand A | - | 10.41 | 11.02 | 7.84 | 7.88 |
| Selling And Marketing Expense | - | 1.51 | 1.68 | 1.90 | 2.05 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Utah Medical Products, Inc.this co. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR |
| - |
| - |
| - |
| - |
| - |
| - |
| $219M |
| -1.83 |
| 1.12 |
| -61.1% |
| -1.49 |
| Pro-Dex, Inc. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Peer Median | - | -2.74 | 0.89 | -17.8% | -1.49 | |